小狗Rosie走了三个月后，她的病历变成了一家AI医疗公司
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - AI-assisted veterinary oncology startup Gamgee raised a $4 million seed round to industrialize personalized mRNA cancer vaccines for dogs, building on an experimental treatment created for founder Paul Conyngham’s dog Rosie. The funding will support a clinical trial, as the approach’s efficacy remains unproven beyond the individual case.
- The workflow sequences tumor and healthy tissue, identifies tumor-specific mutations and neoantigens, and designs a personalized mRNA vaccine for each dog.
- Rosie’s design reportedly used tools including ChatGPT, AlphaFold, and Grok, but university researchers reviewed the data and manufactured the vaccine.
- Gamgee aims to shorten and coordinate the full treatment pipeline—from veterinary intake and sequencing through production, dosing, and follow-up—not merely the AI design stage.
- Australian clinical studies will determine whether the N-of-1 approach produces evidence acceptable to veterinarians and regulators; Rosie’s temporary remission alone is not sufficient proof.
Sources (1)
小狗Rosie走了三个月后，她的病历变成了一家AI医疗公司
TL;DR - AI-assisted veterinary oncology startup Gamgee raised a $4 million seed round to industrialize personalized mRNA cancer vaccines for dogs, building on an experimental treatment created for founder Paul Conyngham’s dog Rosie. The funding will support a clinical trial, as the approach’s efficacy remains unproven beyond the individual case.
- The workflow sequences tumor and healthy tissue, identifies tumor-specific mutations and neoantigens, and designs a personalized mRNA vaccine for each dog.
- Rosie’s design reportedly used tools including ChatGPT, AlphaFold, and Grok, but university researchers reviewed the data and manufactured the vaccine.
- Gamgee aims to shorten and coordinate the full treatment pipeline—from veterinary intake and sequencing through production, dosing, and follow-up—not merely the AI design stage.
- Australian clinical studies will determine whether the N-of-1 approach produces evidence acceptable to veterinarians and regulators; Rosie’s temporary remission alone is not sufficient proof.